Stockwinners Market Radar for October 12, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:09 EDT Cathie Wood's ARK Investment bought 133K shares of Intellia Therapeutics today

20:08 EDT Cathie Wood's ARK Investment bought 516K shares of Ginkgo Bioworks today

19:50 EDT Mitcham Industries trading halted, news pending

18:02 EDT Pinterest director Jordan sells 17,500 class A shares - In a regulatory filing, Pinterest director Jeffrey Jordan disclosed the sale of 17,500 class A common shares of the company on October 11 at a price of $28.6344 per share.

17:29 EDT Rite Aid to delay filing 10-Q - The company states in NT 10-Q filing: "As previously disclosed by the Company, including in its Quarterly Report on Form 10-Q for the quarter ended June 3, 2023, filed with the U.S. Securities and Exchange Commission on July 11, 2023, the Company has been engaged in reviewing and continues to review strategic alternatives to recapitalize, refinance or otherwise optimize its capital structure, which may ultimately result in the Company pursuing one or more significant corporate transactions or other remedial measures. As part of the preparation of the Form 10-Q, the Company is conducting an impairment charge analysis, which, together with the processes involved in the Ongoing Review, require significant resources from the Company's financial, accounting and administrative personnel. As a result, the Company is unable to complete and file the Form 10-Q by the prescribed due date without unreasonable effort and expense."

17:26 EDT Cassava Sciences down 48% after simufilam researcher was accused of misconduct

17:03 EDT Lockheed Martin awarded $379.58M Navy contract order - Lockheed Martin was awarded a $379.58M firm-fixed-price order against a previously issued basic ordering agreement. This order provides for the production and delivery of eight MH-60R aircraft for the government of Spain. Work is expected to be completed in March 2027. Foreign Military Sales customer funds in the amount of $379.58M will be obligated at the time of award, none of which will expire at the end of the current fiscal year. Naval Air Systems Command is the contracting activity.

17:01 EDT Northwest Natural Gas increases dividend to 48.75c per share - Northwest Natural Gas has increased the quarterly dividend to 48.75c per share on the company's common stock. The dividend will be paid on Nov. 15 to shareholders of record on Oct. 31. The company's indicated annual dividend rate is $1.95 per share.

16:55 EDT Opal Fuels names Scott Contino interim CFO - OPAL Fuels "announced that Ann Anthony has notified the Company of her intention to resign as the Company's Chief Financial Officer to pursue another professional opportunity, and that Scott Contino, CFO of the Company's sponsor, Fortistar, has been appointed as interim CFO. Mr. Contino has been part of the OPAL Fuels business since inception, and previously served as the CFO of its predecessor parent company. Ms. Anthony's departure date has not yet been determined but remains under discussion between the Company and Ms. Anthony. Mr. Contino will assist Ms. Anthony during the transition and take on the CFO role on the date of Ms. Anthony's departure, once determined. The Board of Directors of the Company has commenced a search process for a permanent CFO."

16:45 EDT 60 Degrees Pharmaceuticals Inc trading resumes

16:38 EDT Costco CFO sells $1.13M in common stock - In a regulatory filing, Costco disclosed that its CFO James Klauer sold 2K shares of common stock on October 10th in a total transaction size of $1.13M.

16:34 EDT Relay: Lirafugratinib data show durable response across multiple FGFR2 tumors - Relay Therapeutics announced initial clinical data for RLY-4008 or lirafugratinib, in patients with FGFR2-altered solid tumors. The data demonstrate activity across several sub-groups, including patients with FGFR2-fusion tumors and patients with FGFR2-altered HR+/HER2- breast cancer. These data are being presented today at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics."These data provide important early evidence that RLY-4008, or lirafugratinib, has the potential to help both patients with FGFR2-fusion cholangiocarcinoma as previously reported, as well as those with multiple other types of FGFR2-altered tumors," said Don Bergstrom, M.D., Ph.D., President of R&D at Relay Therapeutics. "We are excited by the potential for lirafugratinib to help many more patients and are focused on advancing this opportunity as well as our PI3Ka programs, with the initiation of a RLY-2608 triplet combination trial this year."...The company will continue to prioritize and expand further PI3Ka mutant selective development, including:RLY-2608: continue ongoing ReDiscover trial with focus on RLY-2608 + fulvestrant cohorts...With the decision to pause CCA commercial readiness and RLY-2139 development, Relay Therapeutics expects its cash, cash equivalents and investments will be sufficient to fund its current operating plan into the second half of 2026.

16:31 EDT Comtech jumps 8% to $8.76 after Q4 earnings beat

16:27 EDT Credicorp: Quiet period for 3Q23's earnings release begins October 19th - Credicorp announces that in accordance with its corporate disclosure policies and to prevent any leaks of financial results and ensure fairness, the Company will start the quiet period for 3Q23's earnings release on October 19th. This period will end on the date of the release, November 3rd. During the quiet period, the Company will not disclose any financial information, comment on financial results, or respond to related questions.

16:18 EDT Sellas Life Sciences provides update on galinpepimut-S trial - Sellas Life Sciences provided an update on its Phase 3 open-label registrational clinical trial for galinpepimut-S, or GPS, in patients with acute myeloid leukemia, or AML, who have achieved complete remission following second-line salvage therapy. The company expects to complete enrollment in the REGAL study, other than the 20-25 patients anticipated to be enrolled in China, in November. The number of patients needed for the pre-specified interim and final analyses have already been enrolled. The interim analysis is on track to occur in late 2023 or early 2024 and the final analysis is on track to occur by the end of 2024. Because these analyses are event driven, they may occur at a different time than currently expected. The company anticipates that 3D Medicines, its commercialization partner for GPS in Greater China, will begin enrolling patients in China in the REGAL study in the fourth quarter which will trigger two development milestone payments totaling $13M. The Company and 3D Medicines had previously projected that enrollment in China would commence in the third quarter of 2023, however, unforeseen supply-chain delays in China impacted the projected timeline. 3D Medicines has successfully obtained all regulatory permits, recruited investigators, and set up an expansive network of 11 treatment centers across China for participation in the REGAL study. The next meeting of the Independent Data Monitoring Committee for the REGAL study is scheduled for the end of November.

16:16 EDT EQT Corporation increases quarterly dividend 5% to 15.75c per share - EQT Corporation declared a quarterly cash dividend of 15.75c per share, payable on December 1 to shareholders of record at the close of business on November 8. This represents a 5% increase to EQT's regular quarterly cash dividend to 63c per share on an annualized basis.

16:13 EDT Groupon up 3% at $11.30 following Roth MKM initiation at Buy

16:10 EDT 60 Degrees Pharmaceuticals Inc trading halted, news pending

16:08 EDT Ouster continues patent case against Hesai in district court - Ouster (OUST) issued a statement relating to the company's complaint filed with the U.S International Trade Commission and the investigation into the unfair trade practices of Hesai Group (HSAI) and related entities: "Ouster previously filed its patent infringement case against Hesai in the United States District Court for the District of Delaware in April 2023, but this case was stayed pending the results of a separate ITC investigation filed at the same time. On October 11, the ITC announced that the investigation is terminated to allow for arbitration before any ruling was made on the merits of the patent infringement complaint. As a result, the stay on the infringement case in Delaware will be lifted and the case will recommence. Ouster looks forward to expeditiously addressing the merits of its patent infringement claims in Delaware or through arbitration. The Company will continue to vigorously enforce its patents and seeks to bar all infringing products from the United States in all venues."

16:07 EDT Agree Realty increases monthly dividend 2.9% to 24.7c per share - Agree Realty has declared a monthly cash dividend of 24.7c per common share. The monthly dividend reflects an annualized dividend amount of $2.964 per common share, representing a 2.9% increase over the annualized dividend amount of $2.880 per common share from 4Q22. The dividend is payable November 14 to stockholders of record at the close of business on October 31. Additionally, the company has declared a monthly cash dividend on its 4.25% Series A Cumulative Redeemable Preferred Stock of $0.08854 per depositary share, which is equivalent to $1.0625 per annum. The dividend is payable November 1 to stockholders of record at the close of business on October 20.

16:05 EDT Reynolds Consumer Products names Scott Huckins as next CFO - Reynolds Consumer Products announced the appointment of Scott E. Huckins as the company's CFO, effective November 13, 2023. He is the successor to Michael Graham, who will then shift to an advisory role until his retirement in February 2024. To ensure a successful transition, Mr. Huckins will join the company in an advisory role on October 23, then assume the role of CFO on November 13.

16:00 EDT ElectraMeccanica names Stephen Johnston CFO - ElectraMeccanica Vehicles announced that its CFO, Mark Orsmond will be succeeded, effective immediately, by Stephen Johnston. Orsmond's departure reflects a mutually-agreed transition and allows the outgoing CFO to pursue other interests, while leaving the company's financial reporting, cost controls and balance sheet in superior condition. Stephen Johnston, with whom Orsmond, ElectraMeccanica's Board and the rest of its management team have been working in a consulting role since June, 2023, now will take on the business's CFO responsibilities. Orsmond will continue to assist the company with Johnston's onboarding under a 60-day consulting agreement. "Mark has been a tremendous asset to the Company and our team since I came on board as CEO last December," said Susan E. Docherty, Chief Executive Officer of ElectraMeccanica. "He joined ElectraMeccanica under its prior management team, and we appreciated his institutional knowledge and eye for highly professionalized financial reporting and cost management. We're extremely grateful for his contributions, and for his willingness to assist with Stephen's onboarding. We wish him and his family the best in their next chapter."

15:33 EDT Genius Group reports CEO provides personal funding of up to $4M - Genius Group announces that it has entered into a loan agreement with its CEO, Roger James Hamilton, to provide the company with up to $4M as an interest free loan, to be converted into equity in Genius Group as ordinary shares and upon the same terms at the next Qualified Financing Round. Roger Hamilton, CEO of Genius Group, said: "I founded this company and am fully committed to our mission and future success. As the company continues on its growth path, and as we continue to sign new partnerships and joint ventures that harness cutting-edge technologies to serve our students, users and partners in unique way, I want to ensure our company continues to grow without liquidity constrains while we take the time to ensure we attract the right investors who are aligned with our long-term success."

15:06 EDT Nuvve reports 180 calendar day extension from Nasdaq to regain compliance - Nuvve announced that it has received a 180 calendar day extension, until April 8, 2024, from the Nasdaq Stock Market to regain compliance with Nasdaq's "Bid Price Rule." "The Bid Price Rule stipulates that the bid price of Nuvve's common stock must close at $1.00 per share or more for a minimum of 10 consecutive business days. On April 14, 2023, Nuvve received notice from Nasdaq that based on the previous 30 consecutive business days, Nuvve's listed security no longer met the minimum $1.00 bid price per share requirement. Nuvve will continue to monitor the closing bid price of its common stock and plans to pursue available options to regain compliance with the Bid Price Rule, including potentially pursuing a reverse stock split. If Nuvve authorizes a reverse stock split, it will plan to effectuate the split no later than ten business days prior to the end of the extension in order to timely regain compliance," the company stated.

14:51 EDT Twin Ridge Capital Acquisition Corp trading resumes

14:27 EDT LL Flooring confirms receipt of unsolicited proposal from Live Ventures - LL Flooring Holdings (LL) confirmed that it has received an unsolicited, non-binding proposal from Live Ventures Incorporated (LIVE) to acquire all of the outstanding shares of the company for $5.85 per share in cash. "As previously announced, LL Flooring's Board of Directors has initiated an exploration of strategic alternatives in response to receipt of multiple inbound expressions of interest regarding a potential transaction with the company. As part of this process, the Board will consider a wide range of options for the company including, among other things, a potential sale, merger or other strategic transaction. Consistent with its fiduciary duties and in consultation with its financial and legal advisors, the LL Flooring Board of Directors will carefully review and consider the proposal from Live Ventures in the context of LL Flooring's strategic alternatives process to determine the course of action that it believes is in the best interests of the company and all of its shareholders, which will include inviting Live Ventures to participate in the ongoing strategic review process on similar terms as others. While the strategic alternatives process is ongoing, the company is continuing to execute on its five core growth strategies... LL Flooring shareholders do not need to take any action at this time. LL Flooring does not intend to comment further on Live Venture's unsolicited proposal until the Board has completed its review," the company stated.

12:53 EDT Evolv confirms FTC requested information about marketing practices - In a regulatory filing earlier, Evolv Technologies disclosed that on October 12, the company announced that the U.S. Federal Trade Commission had requested information about certain aspects of its marketing practices. "We are pleased to answer their questions, as well as educate them about our mission to make communities safer and more secure. Like many companies, when Evolv receives inquiries from regulators, our approach is to be cooperative and educate them about our company. The company stands behind its technology's capabilities and performance track record, and is proud to partner with hundreds of security professionals to add a layer of advanced technology to their safety plan," Evolv stated. Reference Link

12:31 EDT PMV Pharmaceuticals' PC14586 Phase 1 data demonstrates anti-tumor activity - PMV Pharmaceuticals announced updated Phase 1 results from its ongoing Phase 1/2 PYNNACLE clinical trial that showed PC14586 achieved efficacy in heavily pretreated patients across multiple tumor types and was well tolerated with a favorable safety profile. Results are being presented in a late-breaking poster session today by Alison M. Schram, M.D., Medical Oncologist at Memorial Sloan Kettering Cancer Center and PYNNACLE Study Investigator, at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics taking place in Boston, Massachusetts. Dr. Schram commented, "Patients with a solid tumor harboring a TP53 Y220C mutation are in need of new treatment options, as currently there are no approved therapies targeting p53. The safety and efficacy data presented today demonstrate the potential of PC14586 to address a high unmet need in patients with TP53 Y220C-positive advanced solid tumors." Study highlights include: Confirmed responses were observed in patients whose tumors were TP53 Y220C and KRAS wild-type in the efficacious dose range, in multiple tumor types including ovarian, breast, prostate, small-cell lung, and endometrial cancer. Median duration of response was seven months. Overall response rate per RECIST version 1.1 was 38% at the Recommended Phase 2 Dose of 2000 mg daily and 34% in the efficacious dose range. A RP2D of 2000 mg once daily was selected based on overall safety, pharmacokinetics, and efficacy in alignment with the U.S. Food and Drug Administration at an End of Phase 1 meeting held in Q3 2023. The planned Phase 2 patient population includes TP53 Y220C and KRAS wild-type patients. PMV plans to initiate a registrational Phase 2 trial in early 2024.

12:02 EDT Stagwell acquires Left Field Labs, terms not disclosed - Stagwell has acquired Left Field Labs, a digital agency at the intersection of technology and human-centric design. Left Field has spent over 15 years building a comprehensive digital offering and joins Stagwell's Constellation Network to help guide clients in designing and implementing responsibly designed AI systems, digital transformation initiatives, and immersive consumer experiences. As part of the Constellation network, Left Field will launch an expansive suite of offerings that seamlessly weave together AI, digital transformation, and immersive experiences to help companies foster organizational growth and enterprise-wide change. These offerings will guide clients in harnessing AI capabilities adeptly while maintaining enterprise security; transforming product strategy; and creating solutions that enhance workflow efficiencies. Terms of the deal were not disclosed.

12:00 EDT Luxfer falls -11.0% - Luxfer is down -11.0%, or -$1.30 to $10.47.

12:00 EDT Mytheresa rises 7.0% - Mytheresa is up 7.0%, or 22c to $3.37.

12:00 EDT LL Flooring rises 43.0% - LL Flooring is up 43.0%, or $1.26 to $4.19.

11:52 EDT Ubisoft says new 'Assassin's Creed' biggest new gen launch in unit sales - Yesterday, Ubisoft (UBSFY) said that its latest release "Assassin's Creed Mirage" is the biggest new generation launch in terms of unit sales to date at Ubisoft, new generation referring to the PlayStation 5 (SONY) and Xbox Series X/S (MSFT) consoles. Reference Link

11:34 EDT Perception Capital Corp II trading halted, volatility trading pause

11:23 EDT AMC CEO says personal matter related to prior extortionist's attack 'closed' - Adam Aron, CEO of AMC Entertainment, stated earlier in a post to X, formerly known as Twitter: "Throughout my long career, I have successfully led many prominent companies and am proud of my impeccable reputation. In recent years, AMC's millions of retail shareholders have played a central role in my life. Your passion for our company is one of my key motivators in doing all I can to help AMC survive so that eventually we can thrive. Because you are so important to me, there is a matter I want to share with you. By definition, I live my life in the public eye. Unfortunately, last year I became the victim of an elaborate criminal extortion by a third party who was unknown to me related to false allegations about my personal life. Rather than give in to blackmail, I personally engaged counsel and other professional advisors and reported the matter to law enforcement. I did so knowing I risked personal embarrassment. But with my access to resources, if I did not stand up against blackmail, who could? A vigorous federal criminal investigation ensued which resulted in the extortionist being arrested, convicted of a felony, and spending nearly a year in jail. At the time of the arrest, the U.S. Attorney for the Southern District of New York commended my having reported the matter to the FBI and the U.S. Department of Justice. This was entirely a personal matter. I was asked by law enforcement to keep this matter confidential during their investigation and subsequent court case. Shortly after the extortionist's July 2023 sentencing, I informed AMC's Board of Directors which thoroughly reviewed these events with independent outside counsel at WilmerHale. As I said above, this indeed was entirely a personal matter, and the matter is closed. And now, I am reporting this to all of you. I could not end this message without again thanking you for your support -- as well as emphasizing my extreme gratitude to the U.S. Attorney's Office for the Southern District of New York and to the FBI for their diligent, skillful, and professional handling of this unfortunate matter." Reference Link

10:56 EDT Veon says 'sole and rightful owner of Kyivstar' - VEON Ltd. issued clarification regarding the developments in Ukraine, in response to recent press reports and in order to address the questions raised by VEON's international debt and equity investors, stating: "On October 6, the Security Services of Ukraine, or SSU, announced that the Ukrainian courts are seizing all 'corporate rights' of Mikhail Fridman, Peter Aven and Andrei Kosogov in 20 Ukrainian companies that these individuals beneficially own, while criminal proceedings, unrelated to Kyivstar or VEON, are in progress. This announcement was incorrectly characterized by some Ukrainian media as a 'seizure' or 'freezing' of 'Kyivstar's assets'. On October 9, Ukrainian media further reported, with a headline which incorrectly targets Kyivstar, that the Ministry of Justice of Ukraine is separately finalizing a lawsuit in the Ukraine High Anti-Corruption Court to confiscate any Ukrainian assets of M. Fridman. At present, neither VEON nor Kyivstar have received any official communication from the Ukrainian authorities or courts regarding these matters. The only information that VEON has at the moment is from its share registrar in Ukraine, which confirms that any ownership changes to Kyivstar are currently not permitted. While VEON does not comment on unconfirmed reports in principle, the escalation of the rhetoric and the questions that VEON received from its debt and equity investors necessitate that the company clarifies the following facts. First and foremost, VEON is and remains Kyivstar's sole and rightful owner. None of the individuals mentioned in the SSU announcement referenced above own any shares in VEON or Kyivstar... Kyivstar, with the full support of its parent company VEON, continues to serve its 25 million customers and keeps not only its own customers, but also the broader country connected through extremely challenging conditions, with 94% network availability and full operational integrity in line with the national security priorities of Ukraine. VEON and Kyivstar are fully committed to continue serving Ukraine, as demonstrated by the USD 600 million investment pledge for the recovery and reconstruction of the country."

10:23 EDT Delta Air Lines: Engine, airframe turnaround times remain elevated

10:20 EDT Delta sees 1Q24 domestic capacity flat to slightly down y/y

10:10 EDT Delta Air Lines: Business travel continues to steadily improve

10:04 EDT Delta CEO: Inbound, outbound flights to Tel Aviv suspended through October 31 - Comments taken from Q3 earnings conference call.

10:00 EDT Amazon: Prime members purchased over 25M items with same-day, next day delivery - Amazon said Prime members saved more than $1B across millions of deals during Prime Big Deal Days on October 10 and 11. For the second year, Amazon kicked off the holiday shopping season with a two-day exclusive shopping event for Prime members, helping members get everything they want and need, quickly and reliably across hundreds of millions of items worldwide. "Prime Big Deal Days was a strong start to the holiday shopping season, offering Prime members an exclusive early opportunity to save and surpassing our expectations. This event outpaced last year's holiday kick-off event, with more Prime members shopping this year," said Doug Herrington, CEO of Worldwide Amazon Stores. "Millions of Prime packages in the U.S. have already been delivered, and we'll continue to offer fast, free delivery across our wide selection throughout the holidays. Thank you to our employees and selling partners around the world for their continued commitment to our customers as we head into this busy shopping season. On the first day of Prime Big Deal Days, Amazon U.S. Prime members purchased more than 25 million items with same-day or next-day delivery, with hundreds of thousands of items delivered within four hours of purchase. In addition, Prime members ordered more than 150 million items from independent sellers in Amazon's store, most of which are small and medium-sized businesses. Reference Link

10:00 EDT Commercial Metals falls -8.5% - Commercial Metals is down -8.5%, or -$4.11 to $44.23.

10:00 EDT Annovis Bio rises 7.1% - Annovis Bio is up 7.1%, or 55c to $8.25.

10:00 EDT LL Flooring rises 33.4% - LL Flooring is up 33.4%, or 98c to $3.91.

09:58 EDT ADiTx Therapeutics trading resumes

09:53 EDT ADiTx Therapeutics trading halted, volatility trading pause

09:51 EDT Knightscope announces two sales for K5 ASRs - Knightscope announces two more new sales for its K5 Autonomous Security Robots at a hotel in Athens, Georgia, and a Pre-K school in Vancouver, Washington.

09:47 EDT Alpha Metallurgical falls -7.9% - Alpha Metallurgical is down -7.9%, or -$19.87 to $230.54.

09:47 EDT Livent rises 5.4% - Livent is up 5.4%, or 97c to $18.78.

09:47 EDT LL Flooring rises 30.2% - LL Flooring is up 30.2%, or 89c to $3.81.

09:32 EDT Tempest Therpeutics trading halted, volatility trading pause

09:26 EDT Connexa Sports announces 'continued growth' for Tennis Ball Launcher - Connexa Sports Technologies announced that its flagship consumer product, Slinger Bag, continues to deliver strong consumer demand for its original Tennis launcher, a single product offering, which debuted in late summer 2020 and has seen cumulative sales through to today, in excess of $40M.

09:24 EDT Terreno acquires industrial property in Red Hook Brooklyn for $27.5M - Terreno Realty acquired an industrial property located in Red Hook, Brooklyn, New York on October 11 or a purchase price of approximately $27.5M. The property consists of one industrial flex building containing approximately 96,000 square feet on 3.8 acres. The property is at 185 Van Dyke Street, on the Upper New York Bay waterfront, provides two dock-high and ten grade-level loading positions and off-street parking for 26 cars. The property is 66% leased to 19 tenants and the estimated stabilized cap rate is 6.4%.

09:20 EDT American Battery selected as battery Recycler for national eWaste program - American Battery (ABAT) will serve as the lithium-ion battery recycler for Pyxera Global and Terra's Done with It pilot program, sponsored by FedEx (FDX), to test the viability of recovering used electronics, or e-waste. The pilot program aims to develop circular business models for the logistics industry. The pilot program will accept items through December 15. Terra's Done with It mail-in recycling program will facilitate the nationwide collection of laptops and tablets and will direct the donated devices to a secure FedEx facility located in middle Tennessee. If a donated device is repairable, it will be sent to Electronics Recycling Solutions, a Nashville-area social enterprise that is also R2v3-certified and dedicated to training adults with developmental disabilities in high-demand repair skills. The lithium-ion batteries will be recycled at ABTC's commercial-scale, lithium-ion battery recycling facility located in the Tahoe-Reno Industrial Center in Nevada.

09:19 EDT Kairous Acquisition announces additional contribution to trust account - Kairous Acquisition Corp. announced that Kairous Asia Limited, the Company's initial public offering sponsor, has deposited into the Company's trust account an aggregate of $120,000, in order to extend the period of time the Company has to complete a business combination for an additional one month period, from October 16, 2023 to November 16, 2023. The Company issued a promissory note to Sponsor with a principal amount equal to the amount deposited. The promissory note bears no interest and will be converted into the Company's ordinary shares at a price of $10.10 per share at the closing of a business combination by the Company. The purpose of the extension is to provide time for the Company to complete a business combination.

09:16 EDT Mangoceuticals announces launch of MangoRx Affiliate Marketing Program - Mangoceuticals announced the official launch of its affiliate marketing program via its newly designed website at www.MangoRevenue.com. MangoRx has selected Impact Radius as its premier affiliate automation and influencer management platform. Impact Radius has worked with companies providing cutting-edge backend software management for affiliate marketing programs as well as an actively managed recruiting database of more than 7 million influencers interested in helping emerging brands blossom and thrive. Impact Radius will also handle the management of toolkits for affiliate marketing partners. Furthermore, MangoRx has partnered with Hamster Garage, a partnerships and affiliate management agency to assist MangoRx in building and managing its partnership programs. Hamster Garage has taken on over 40,000 affiliate marketing partner relationships to help partner-clients raise over $9.3 billion, with its average program driving 300% efficiency across the project. Hamster Garage will drive affiliate discovery and interest, coordinating and managing affiliate relationships for MangoRx.

09:13 EDT Lexaria Bioscience granted two Canadian patents - Lexaria Bioscience has been granted two new patents by the Canadian Intellectual Property Office, increasing Lexaria's complete patent portfolio to 37 granted patents. Canadian Patent #2,984,917, "Stable Ready-to-drink Beverage Compositions Comprising Lipophilic Active Agents" was granted on September 26, 2023, and expires December 1, 2036. This patent recognizes Lexaria's innovations in delivering lipophilic active drugs and active molecules suspended in a water-based format. Lexaria's DehydraTECH technology can be used in both dry formats such as capsules and pills, as well as in liquid formats such as drops, tinctures and also beverages including consumer beverages. This is Lexaria's 6th granted patent in its patent family #3. Canadian patent #3,111,082, "Lipohilic Active Agent Infused Tobacco Leaves and/or Tobacco Materials and Methods of Use Thereof" was granted on August 29, 2023, and expires on September 13, 2039. This patent recognizes Lexaria's innovations in infusing tobacco leaves directly with drugs or active molecules such as nicotine with or without cannabinoids for potential applications such as treating nicotine addiction. This is Lexaria's 1st granted patent in its patent family #14.

09:07 EDT Nokia, Colt showcase power of PSE-6s coherent optics - Nokia announced that Colt Technology Services successfully trialed Nokia's sixth generation super-coherent optics to increase the scale and performance of its optical network. Using Nokia's PSE-6s solution, Colt successfully completed a long-haul production network trial achieving 800G line capacity over a 1,500 Km network connecting Madrid, Spain to Lisbon, Portugal. This capability will enable Colt to increase the capacity while reducing the total cost of ownership and improving power efficiency. Rafael DeFermin, SVP Network Infrastructure, Europe Regional Business Center at Nokia, said: "With data volumes growing exponentially every year, there continues to be an increased focus by operators on the cost and power consumption per bit. But it's not just about meeting the demands of today's networks, it's also about shaping the future of connectivity. Nokia's PSE-6s solution allows operators like Colt to position themselves at the forefront of the industry and use their existing network to deliver the unmatched speed, efficiency and reliability essential for meeting both current and future evolving customer demands."

09:07 EDT Apple Hospitality REIT acquires Courtyard by Marriott Salt Lake City Downtown - Apple Hospitality REIT announced the acquisition of the 175-room Courtyard by Marriott Salt Lake City Downtown for approximately $48.1M or $275,000 per key; the 159-room Hyatt House Salt Lake City/Downtown for approximately $34.3M, or $215,000 per key; and a corresponding 346-space parking garage for approximately $9.1M, which serves both hotels as well as the surrounding area. "While overall industry transaction volume remains muted, the strength of our operating performance and our relative liquidity position have provided us with unique opportunities to pursue accretive acquisitions and to grow our portfolio," said Nelson Knight, President, Real Estate and Investments of Apple Hospitality. "The acquisition of the Courtyard and the Hyatt House in downtown Salt Lake City expands our presence within the vibrant Salt Lake market, an area well known for its business-friendly environment, attractive cost of living, cultural attractions and proximity to outdoor recreational activities, which has seen significant economic growth in recent years and is poised for continued expansion. By leveraging the strength of our industry relationships and our deep transaction experience, we are expanding our portfolio in ways that we believe will meaningfully enhance shareholder value over the long term. We are actively underwriting additional opportunities and are well positioned to further add to our portfolio in the coming months." ...In addition, the Company today announced that it has two additional hotels under contract for purchase, the 146-room Residence Inn by Marriott Seattle South/Renton for approximately $55.5 million, or $380,000 per key, and the 192-room Embassy Suites by Hilton South Jordan Salt Lake City for approximately $36.8 million, or $191,000 per key. Assuming all conditions to closing are met, the Company anticipates acquiring the hotel in Renton and the hotel in South Jordan during the fourth quarter 2023. Following the acquisition of the downtown Salt Lake City hotels, the Apple Hospitality hotel portfolio includes 222 hotels with 29,263 guest rooms geographically diversified throughout 37 states

09:06 EDT MGO Global appoints Jeff Lerner as strategic advisor to leadership team - MGO Global welcomed Jeff Lerner to the MGO team as a key corporate advisor to the Company's leadership team, effective immediately. Currently, Lerner serves as CEO of Misnomer, a fractional Chief Marketing Officer consulting firm he founded in 2017 to advise start-up companies on developing effective branding, marketing and public relations strategies.

09:05 EDT Bit Origin mined 15.9 bitcoins in September - Bit Origin provided its production and operation update for September 2023. Operation Update: In September 2023, the Company ceased its operation in the Indiana facility and gradually moved its operation to the Wyoming facility. As of September 30, 2023, the total mining hash rate stands at 320 PH/s with 3,200 miners installed in the Wyoming facility, with the remaining 1,050 miners waiting to be deployed. Bitcoin Production and Revenue: The Company mined 15.9 Bitcoins and achieved a revenue of $416,444 in September 2023. Mining Sites Development: As of September 30, 2023, the Company operates in a mining data center facility in Wyoming, which the Company is an investor. The Company ceased its operation in the mining facilities in Georgia from December 2022 and Indiana from September 2023 respectively.

09:05 EDT Live Ventures proposes to acquire LL Flooring for $5.85 per share - Live Ventures (LIVE) released the below correspondence sent to LL Flooring (LL), which details Live Ventures Incorporated's $5.85 per share all-cash acquisition proposal. "Live Ventures Incorporated ("Live Ventures" or "we") is pleased to present a non-binding offer for a transaction between Live Ventures and LL Flooring Holdings, Inc. ("LL Flooring" or the "Company"). Our goal is to facilitate constructive discussions with the Board and enter into a mutually agreeable transaction that is in the best interests of all LL Flooring shareholders. We would also like to disclose that the Isaac Capital Group, an investment firm I personally control and manage, has made a significant investment in LL Flooring and is a top-five shareholder, currently owning over 4% of the Company's outstanding common stock. As described more fully below, our proposal to acquire 100% of LL Flooring shares in an all-cash offer for $5.85 per share represents a 106% premium to the Company's closing share price as of October 6, 2023. For the reasons we outline, we believe this proposal is the best path forward for all Company stakeholders - and we are prepared to move quickly to execute it together. As a diversified, publicly traded holding company, Live Ventures has considerable experience working with retailers that have faced similar challenges LL Flooring is confronted with today. It is encouraging that the Board has recognized these headwinds by announcing the initiation of a strategic alternatives process, especially considering the material losses shareholders have experienced over the past several years. We fear that the Company's stock price will continue its decline unless LL Flooring enters into a transaction with a well-capitalized acquiror that has extensive experience working with synergistic retailers in the near term. Live Ventures seeks to acquire companies and partner with management teams that we believe are in need of new ownership and outside capital to support growth and enhance shareholder value. We have a strategic focus on acquisitions of domestic middle-market companies, with Flooring being one of our key segments (currently representing 46% of total 2022 revenue).1 A transaction between Live Ventures and LL Flooring, which includes 442 stores spanning 47 states across the U.S., would therefore be synergistic given our extensive portfolio of flooring companies. Our portfolio includes Marquis Industries, Inc., a leading carpet and hard-surface flooring products manufacturer for which we have grown revenue levels approximately 117% since acquiring it in 2015, as well as Flooring Liquidators, Inc., a retailer and installer of floors, carpets and countertops, which we acquired earlier this year for $85 million. We believe that adding LL Flooring to the Live Ventures portfolio will help the Company thrive and be a major catalyst for our buy-build-hold strategy, which has delivered enhanced shareholder value since I joined as Chief Executive Officer in 2012 and began refocusing our company's strategy. Since then, Live Ventures has delivered approximately 237% in total shareholder returns, strong revenue, earnings and balance sheet growth.2 We have a successful track record acquiring historic brands and working closely with existing management teams, boards of directors and large, diverse employee bases to deliver superior value for stakeholders. We firmly believe we can deliver the same results for LL Flooring. Based on public information, we have conducted an extensive analysis of the opportunity presented by LL Flooring. As a result of our findings, and subject to completing confirmatory diligence, we are pleased to submit this non-binding indication of interest (the "Indicative Proposal" or "Offer") to acquire 100% of the issued and outstanding shares of common stock of the Company for $5.85 per share in cash (the "Offer Price"), which equals an aggregate equity value of approximately $194.4 million. This Offer is based on our current understanding of the Company's capital structure, which comprises approximately 33.2 million fully diluted shares of common stock. We believe that this Indicative Proposal represents compelling value for the Company and its shareholders, with the Offer Price corresponding to a 106% premium to LL Flooring's closing price per share of $2.84 as of October 6, 2023, providing a significant premium relative to recent share price performance. The Offer Price reflects a 94.4% premium over the 30-day volume-weighted average share price. Importantly, our Offer provides the Company's shareholders with certainty, full and fair value and immediate liquidity. Closing would be subject only to LL Flooring shareholder approval, as well as other customary closing conditions for a transaction of this nature with no financing condition or contingency. The Indicative Proposal is subject to focused confirmatory diligence, including finalizing views with our team on customer financial and operational due diligence and customary accounting and legal due diligence. This transaction is a top priority for Live Ventures and we are prepared to work at an expedited pace to reach an agreement with you. We have engaged Vinson & Elkins as legal counsel for this transaction. The Indicative Proposal has been discussed with our Board of Directors and we are prepared to dedicate all resources necessary to complete our due diligence and negotiate definitive transaction documentation in parallel. Given our advanced preparation and commitment, we believe that we could expeditiously announce a transaction assuming cooperation between the parties. We have a strong desire to align on this timeframe as we are deferring other strategic initiatives to focus on completing a transaction with LL Flooring. In consideration for the time, effort and expense incurred and anticipated to be incurred by Live Ventures in connection with pursuing a transaction, we would expect LL Flooring to enter into a customary exclusivity agreement with Live Ventures pursuant to which, among other things, LL Flooring would agree to cause its affiliates, directors, officers, employees, advisors and other representatives not to: (i) initiate, solicit, or knowingly encourage or knowingly facilitate the submission of any proposal for a potential alternative transaction, (ii) engage in negotiations with respect to any potential alternative transaction or any inquiries regarding a potential alternative transaction, or (iii) provide any information to any person or entity (other than Live Ventures or any representatives of Live Ventures) in connection with any potential alternative transaction or any inquiries regarding a potential alternative transaction for an agreed period of time. It is understood that this letter represents our non-binding indication of interest and is not subject to acceptance nor is in any way binding on any party. There can be no guarantee that any transaction will be entered into or completed. A binding commitment between Live Ventures and the Company would result only from the execution of mutually agreed upon definitive transaction documentation. We would like to reiterate our respect for LL Flooring and its leadership and our enthusiasm for pursuing this transaction. We firmly believe that Live Ventures would be the best partner for the Company given our experience, capabilities and track record of value creation as outlined in this letter. We believe that this all-cash offer presents a highly compelling transaction for all LL Flooring shareholders and stakeholders. We would very much appreciate the opportunity to further discuss this Offer in further detail with you, as well as your financial and legal advisors. We are ready to work expeditiously to move forward and execute this compelling transaction."

09:03 EDT LPL Financial welcomes OUCU Investment Services to Institution Services Platform - LPL Financial announced that OUCU Financial's investment program, OUCU Investment Services, has joined LPL's Institution Services platform. OUCU Investment Services is made up of two advisors who collectively service approximately $230 million of brokerage and advisory assets. OUCU Investment Services joins from CUSO Financial Services.

09:02 EDT Boeing, United Airlines, NASA to test SAF benefits - In a collaboration to strengthen sustainability in aviation, Boeing (BA) is partnering with NASA and United Airlines (UAL) for in-flight testing to measure how sustainable aviation fuel affects contrails and non-carbon emissions, in addition to reducing the fuel's life cycle climate impact. Boeing's second ecoDemonstrator Explorer, a 737-10 destined for United Airlines, will fly with 100% SAF and conventional jet fuel in separate tanks and alternate fuels during testing. NASA's DC-8 Airborne Science Lab will fly behind the commercial jet and measure emissions produced by each type of fuel and contrail ice particles. NASA satellites will capture images of contrail formation as part of the testing. The researchers aim to understand how advanced fuels, engine combustor designs and other technologies may reduce atmospheric warming. For example, tests will assess how SAF affects the characteristics of contrails, the persistent condensation trails produced when airplanes fly through cold, humid air. While their full impact is not yet understood, some research has suggested certain contrails can trap heat in the atmosphere.

08:51 EDT Safety Shot reports results from product test of Safety Shot - Safety Shot reported results from a product test of Safety Shot, a patented beverage that helps people feel better faster by reducing blood alcohol content and boosting clarity. A study was conducted with volunteers where subjects were served alcohol for one hour, then asked to stop drinking for 30 minutes; after which time volunteers went through a variety of sobriety tests and were then given a breathalyzer to measure their blood alcohol content. Immediately following the tests, volunteers drank 6 ounces of Safety Shot and waited 30 minutes before repeating the same sobriety tests. Participants represented a diverse group composed of males and females from a variety of ethnicities and races. The control group participants were allowed to drink for at least one hour, then wait for approximately five minutes, and rinse their mouth with fresh water two times to ensure no residual alcohol in the mouth and throat. The control participants then took a breathalyzer test, waited at least 30 minutes without a drink, and took a second breathalyzer test. Statistically significant results included the following: The average reduction in percentage of BAC when Safety Shot was administered was 0.079 % BAC/hour compared to 0.01 % BAC/hour for the control group, which did not drink Safety Shot, with a statistically significant p-value of .02428. The results indicate that Safety Shot significantly reduced the percentage of BAC faster on average relative to the control group which was not administered Safety Shot.

08:48 EDT Ascent Solar reduces outstanding debt - Ascent Solar Technologies announced that following the application of the proceeds of the Company's recent public offering, the Company's remaining outstanding debt has been reduced to $1.7M. The paydown aligns with leadership's commitment to reduce leverage as it executes its strategy to increase the efficiency of its thin-film PV module and commercialize its technology with the goal of achieving profitability. Ascent's Board of Directors and CEO Paul Warley collectively invested $380,000 in the recent offering.

08:41 EDT Expion360 enter partnership with Renewable Energy Products Manufacturing - Expion360 partnered with Renewable Energy Products Manufacturing to offer Expion360's new home and commercial e360 solar power storage solutions to REPM's customers. The offering will begin with the launch of a pilot program, with installations expected to start in the first quarter of 2024. Following the pilot program, the Expion360 energy storage solution will be made available to REPM's expanding installation pipeline of thousands of solar-powered homes and businesses across the U.S. The transformative energy storage solution is anticipated to introduce new levels of optimized efficiency and sustainability, and enable home and business owners to benefit from having their own 'micro-grid' of stored energy.

08:38 EDT Foremost Lithium announces results from rock sampling program at properties - Foremost Lithium Resource & Technology announced positive results returned from the rock sampling program on its Peg North, Grass River Claims, Jean Lake, and Zoro properties, including high-grade lithium values and spodumene mineralization at both the Zoro and Jean Lake Property. "The compilation of work has yielded highly promising results from sampling to date, and the team at Dahrouge continues to demonstrate their ability to execute a successful exploration program," said Jason Barnard, President and Chief Executive Officer of Foremost Lithium. "Our 2023 exploration campaign is focusing on our high-quality assets and is supported by extensive geological data. The potential of this fertile area gives us great confidence as we define drill targets in preparation in this upcoming drill program. We look forward to proving results for our company and our shareholders."

08:38 EDT GlucoTrack announces preclinical testing with implantable CGM - Glucotrack announced that it has achieved another milestone in its development of an implantable continuous glucose monitor, CGM, by commencing preclinical animal testing. The Company previously announced the completion and positive results of a laboratory-based feasibility study demonstrating that the CGM sensor design is capable of measuring glucose for at least two years post-implant. Further preclinical testing, in animals, advances the development of the implantable CGM by demonstrating that the sensor design functions as expected after an implant procedure and 30 days thereafter. The objectives of the preclinical animal study were to assess the implant procedure techniques and tools as well as to determine the acute and chronic biological effect of the implant and the implant procedure. At this stage of development, the study was not intended to assess sensor measurement accuracy. The results from the preclinical study have established that the sensor implant procedure takes approximately 15-20 minutes to perform, does not require sophisticated implant techniques or tools, and was able to be completed with no adverse short-term or long-term effect on the animals.

08:37 EDT Atlassian to acquire Loom for $880M in cash, equity awards - Atlassian announced it has entered into a definitive agreement to acquire Loom, the video messaging platform that has amassed more than 25M users and was named among the top 50 of Fast Company's World's Most Innovative companies in 2023. Under the terms of the definitive agreement, Atlassian will acquire Loom for approximately $975M, inclusive of Loom's cash balance, subject to customary adjustments. Total consideration will be comprised of approximately $880M in cash, and the remainder in Atlassian equity awards, subject to continued vesting provisions. Atlassian expects to fund the cash consideration through existing cash balances and the transaction is not expected to have an impact on the company's share repurchase strategy. The transaction is expected to close in the third quarter of Atlassian's fiscal year 2024, subject to customary closing conditions and required regulatory approval. The acquisition is expected to be slightly dilutive to non-GAAP operating margins in fiscal years 2024 and 2025.

08:36 EDT Reborn Coffee appoints Tan to board of directors - Reborn Coffee announced the appointment of Jennifer Tan to its Board of Directors. Tan is currently Chief Executive Officer of Hawaii Volcano Tea LP, a tea farm with multiple locations in the Volcano area of Hawaii Island.

08:35 EDT Amneal adds 2 denosumab biosimilars to U.S. pipeline oncology portfolio - Amneal Pharmaceuticals announced the addition of two denosumab biosimilars referencing both Prolia and XGEVA to its biosimilar pipeline. Denosumab is a monoclonal antibody drug that inhibits bone reabsorption. It is indicated for two major categories of therapy: bone metastasis from various forms of cancer and prevention of bone pain and fractures, including osteoporosis-related injuries. The two denosumab products are being developed by mAbxience, a global biotech company with over a decade of experience in the development, manufacture, and commercialization of biopharmaceuticals. Under the terms of the agreement, mAbxience will fully develop the biosimilar molecule and manufacture it in its state-of-the-art, Good Manufacturing Practice, GMP approved facilities, while Amneal will guide the product through regulatory approval and have exclusive commercialization rights in the United States. Amneal and mAbxience also currently partner on ALYMSYS , a bevacizumab biosimilar. "Our goal is to be a top five player in the U.S. biosimilar space, similar to our leadership position in U.S. retail generics. The financial terms of the transaction were not disclosed, and any incremental expenses associated with these products are contemplated within Amneal's guidance.

08:35 EDT DaVita issues statement on GLP-1 and implications on chronic kidney disease - DaVita (DVA) issued a statement in response to news this week from Novo Nordisk (NVO), manufacturer of Ozempic, a GLP-1 receptor agonist indicated for type 2 diabetes, related to its FLOW study that sought to demonstrate that Ozempic delays progression of chronic kidney disease and lowers the risk of kidney and cardiovascular mortality. "We've been closely monitoring the developments related to GLP-1s, and are excited about the potential benefits this class of drugs could have on society and patients with kidney disease...and whether the results demonstrate improvements over the known effects of SGLT2 inhibitors on kidney disease or the previously announced effects of GLP-1s on cardiovascular mortality...we believe there may be limited application of the FLOW study findings to the overall CKD patient population. We will continue monitoring closely as further evidence becomes available to identify the potential benefit of GLP-1s to those afflicted with kidney disease." Da Vita's understanding of the FLOW clinical trial is that it is unknown which endpoint(s) was positive so as to close the study and whether it was a cardiovascular endpoint, a kidney endpoint, or both. Once released, the detailed results of the FLOW trial will identify which endpoint was proven. If it confirms prior evidence that GLP-1s reduce cardiovascular mortality, any similar findings in the FLOW study would be an additional positive in prolonging life through CKD progression for those taking the therapy. Future trials and research will be required to determine whether any findings derived from the FLOW study could benefit a CKD population beyond those studied in the trial. Novo Nordisk announced that the FLOW study will be released in the first half of 2024 and the SELECT study will be released on or around November 11, 2023.

08:35 EDT Clover Health issued analysis on Clover Assistant, management of diabetes - Clover Health issued an analysis titled Clover Assistant Use and Diagnosis, Treatment, and Progression of Diabetes, which examines the association between use of the company's flagship technology product, Clover Assistant, and earlier physician identification and management of diabetes. "Early diagnosis and treatment of diabetes in the Medicare population is essential for preventing complications, improving overall health and well being, and reducing the economic burden associated with the condition," said Dr. Kumar Dharmarajan, Chief Medical Officer of Clover Assistant. "Our findings demonstrate that use of Clover Assistant is associated with not only earlier diabetes diagnosis and treatment with oral diabetes medications, but also lower blood sugar, insulin use, and hypoglycemia, a major insulin-related complication."

08:34 EDT Emcore completes sale of non-strategic product lines to Photonics Foundries - EMCORE announced the completion of the sale of Broadband segment product lines and its Defense Optoelectronics products to Ortel, a wholly-owned subsidiary of Photonics Foundries. The Broadband lines include the Company's cable TV, wireless, and sensing products. The transaction excludes the Company's Chips business, wafer fabrication facilities, and all assets not primarily related to the product lines that were sold. The signing and closing of the transaction with respect to all U.S. assets occurred simultaneously. Within 45 days following the closing of the transaction, the Company will transfer to the buyer all of the equity interests of each of the Company's subsidiaries in Hong Kong and China. Jeffrey Rittichier, EMCORE's President and CEO commented, "With the sale of the Broadband product lines, EMCORE has completed its transition into a pure-play supplier of inertial navigation solutions to the Aerospace and Defense industry. Photonics Foundries has purchased substantially all of the assets and liabilities that primarily relate to our Broadband products and we wish them great success going forward." Rittichier went on to say, "We'd also like to announce that we completed production of last time orders for our Chips business on schedule and that we shut down our wafer fab operations. We are continuing to work with interested parties on a sale of wafer fab assets and the chip products business line."

08:32 EDT Elys Game Technology introduces online, mobile sports betting brand for the U.S. - Elys Game Technology introduced its new U.S.-focused online and mobile sportsbook brand, www.SportBet.com. The dedicated Elys America platform will offer U.S.-based customers an innovative and immersive way to engage with and bet on their favorite sports with unique features developed to cater to American betting styles. The Company's new mobile brand builds upon its successful partnerships with U.S. regulated sportsbooks and casinos and represents another evolution in its business. Subject to regulatory approvals, the Company expects to expand its online sports betting footprint into multiple U.S. jurisdictions under direct licensing and through market access partnerships in Q4 2023. The Company has previously announced new sportsbook operations in New Jersey and Washington D.C., quickly becoming a recognized international name in regulated gaming within Europe with new operations in Canada and the US.

08:30 EDT DSS CEO looking forward to 'significant growth' for remainder of the year - DSS issued a Letter to Shareholders, which read in part, "On behalf of the management team at DSS, Inc., I am pleased to provide an update on our progress so far this year and our expectations going into the end of the year. While 2023 has been punctuated by global challenges, our collective perseverance and adaptability have been paramount. I remain proud of our resiliency and achievements, and I am looking forward to significant growth remainder of this year and the coming year. We continue to embrace a diversified portfolio and seek out investment opportunities through our extensive channels and strategic partnerships, while also identifying ways to maximize shareholder value. I would like to highlight three specific developments. As previously announced, we are in the late stages of preparing for an Initial Public Offering of our majority owned subsidiary, Impact Biomedical, after distributing four shares of IBIO for every share of DSS held as of the record date of July 10, 2023. Once the IPO has been completed, these stock dividend shares will not be eligible for resale until 180 days from the effective date of the IPO, a restriction that can be lifted at the discretion of IBIO. The structure of this spinoff is designed for DSS to maintain the consolidation of IBIO's financials, ensuring our shareholders receive the benefits of IBIO's success on a go forward basis. Our license agreement with ProPhase Labs (PRPH) is resulting in promising clinical advancement in the development of our Linebacker and Equivir assets. Turning to our product packaging division, Premier Packaging Corporation, Inc., I am elated to report significant growth. Revenue for the first half of 2023 surged to $9.66 million, a 27% increase over the same period in 2022. This growth is a testament to the success of our capital investment in Premier, which has catalyzed operational efficiencies and enriched profit margins. Our commitment to reinforcing our leadership dynamics is evident in the recent enhancement of the management team at DSS Wealth Management, Inc. This deliberate move is aimed at fostering a legacy of investment excellence and scaling our assets under management. As the advisor to DSS AmericaFirst Funds, DSS Wealth added Daniel Lew, CFA, as Chief Investment Officer and Portfolio Manager, Jim Monaghan, CMT, as Chief Operating Officer and Chief Compliance Officer and Michael Cheah, CFA, as Portfolio Manager & Head of Fixed Income. The team collectively has over 100 years of investment industry experience and has worked closely together for almost a decade. We are planning to launch a Total Return Bond Fund, managed by Michael Cheah, to capitalize on the prevailing higher interest rates. Post the Impact Biomedical IPO, we eagerly look forward to introducing our shareholders to our subsequent spinoffs or similar liquidity events. A strategic facet of our approach remains the monetization of our minority interest-be it through mergers or acquisitions. In closing, the trust and support of our shareholders have been instrumental in shaping our journey. I extend heartfelt gratitude for your unwavering belief in DSS, Inc. Here's to the promising road ahead."

08:23 EDT Surf Air Mobility in deal with electric seaglider company REGENT in Miami - REGENT, an "all-electric seagliders company for zero-emission coastal travel," announced that it will partner with Surf Air Mobility to establish a base for seaglider operations in Miami that will provide passenger transport service for South Florida, including routes from Miami, Fort Lauderdale, Palm Beach, and the Caribbean Islands. This deal is the continuation of a longstanding relationship between REGENT and Surf Air subsidiary Southern Airways. The seagliders may be in service as soon as 2027. Approximately 9M passengers travel through South Florida each year across commercial air, ferry, rail, and car. Miami-based seaglider operations could serve as many as 1.5 million passengers annually, connecting travelers between coastal destinations as well as major transportation hubs including Miami International Airport and PortMiami. Surf Air Mobility is uniquely positioned to commercialize and scale new innovative technologies in the regional air mobility space. A Surf Air recently acquired Southern Airways, which REGENT announced earlier this year will take delivery of the first 12-passenger Viceroy seaglider under their Mokulele brand. "We're thrilled to have Surf Air as our premier operating partner in Miami and South Florida," said Billy Thalheimer, co-founder and CEO of REGENT.

08:20 EDT Jerash Holdings, NTX sign agreement to form JV for vertical integration - Jerash Holdings has entered into a definitive agreement to form a joint venture with Newtech Textile. The joint venture company, to be named Jerash Newtech, plans to build a new state-of-the-art fabric facility in Jordan to produce fabrics in a sustainable and innovative manner by utilizing the NTX Cooltrans proprietary waterless coloration technology. The technology is expected to allow for a more than 90 percent water reduction, 65 percent energy savings, 40 percent chemical reduction and over 50 percent carbon footprint reduction in the dyeing process in comparison with traditional coloration approach. The joint venture is anticipated to foster local employment in high-tech-related jobs. Jerash is working with the Jordanian government on possible support and collaboration for the project. Estimated capital expenditures for the joint venture to build the facility will be approximately $30 million, which includes a knitting plant, a dyeing and printing house, laboratory facilities, offices, workers' housing, and related set-up costs over the next several years. Construction is expected to begin in the first half of 2024. Jerash will hold a 51 percent interest, while NTX will hold a 49 percent interest in the joint venture. Jerash and NTX will contribute proportionate amounts of capital to the joint venture.

08:19 EDT Amdocs says Israel operations 'continue without material interruption' - Amdocs issued the following statement regarding the current situation in Israel: "We are horrified by the unconscionable terrorist attack against Israel. Our primary concern is the safety and security of our employees and their families and on providing support to them during this difficult time. We want to sincerely thank our customers, partners, and employees around the world for reaching out to their colleagues at Amdocs to express their support. With revenue from customers in Israel comprising less than 0.5% of total revenue, and the vast majority of our employees outside of Israel, we currently do not expect these events to materially adversely affect our business. While we continue to monitor the situation closely, our operations in Israel continue without material interruption. Additionally, as a global company, with support and development centers around the world, we are able to serve our customers seamlessly, providing 24/7 service and support to all our customers and business operations worldwide, while tending to the needs of our employees and their families in Israel.

08:14 EDT Maris-Tech, ParaZero expand collaboration into defense market for drones - Maris-Tech (MTEK) and ParaZero Technologies (PRZO) announced an expansion of their collaboration. Maris-Tech and ParaZero entered into a letter of intent pursuant to which the companies will collaborate to develop a unified product, integrating safety technology and predictive maintenance. In addition, the companies will explore the possibility of enhancing the capabilities of ParaZero's failure prediction and emergency safety system, utilizing the AI acceleration capabilities in Maris-Tech's original equipment manufacturer products. Commenting on the collaboration, Israel Bar, Maris-Tech's CEO, said, "Safety in drone systems is paramount in the defense industry. Our collaboration with ParaZero ensures advanced safety measures, underlining our commitment to being at the forefront of edge technologies."

08:11 EDT Ocean Biomedical, Virion Therapeutics form joint venture - Ocean Biomedical and Virion Therapeutics announced they have entered into a joint venture to accelerate and expand Virion's clinical-stage program and pipeline, with the goal of finding cures for patients with cancer and chronic infectious diseases. Virion has begun enrolling a multi-national, first-in-humans study, "VRON-0200," for the treatment of persons with chronic hepatitis B virus infection, with the goal of providing a functional cure for a disease that affects over 300 million patients worldwide. Additionally, Virion has IND-enabling activities for their oncology program underway. "We are pleased to be entering into this joint venture with Virion. Altering T cell activation to significantly improve immune responses, and subsequently treatment outcomes, is highly innovative and an exciting new technology with a wide array of potential uses for both cancer and chronic infectious diseases," said Dr. Chirinjeev Kathuria, Ocean's Executive Chairman and co-founder. "We've been impressed with Virion's clinical development expertise and their ability to advance the lead VRON-0200 Chronic HBV program into clinical trials and are looking forward to seeing the first clinical data from this program within the next few months. We are also excited to help support their oncology program, which is targeted for IND submission in the next 9 months. We believe there is great synergy between the companies and that the team and corporate infrastructure at Ocean can help Virion accelerate their development programs, and Virion can assist Ocean in advancing our programs into the clinic - with our joint goal of bringing new treatment options to patients affected by cancer and infectious diseases."

08:10 EDT InMode falls 15% to $23.66 after weak Q3 guidance, FY23 sales outlook cut

08:09 EDT CoreCivic enters into amendment, extension of bank credit facility - CoreCivic entered into a Fourth Amended and Restated Credit Agreement dated October 11, 2023, by and among CoreCivic, as Borrower, certain lenders party thereto from time to time, and the administrative agent for the lenders, or the New Bank Credit Facility. The New Bank Credit Facility effectively replaces CoreCivic's Third Amended and Restated Credit Agreement dated May 12, 2022. The New Bank Credit Facility is in the aggregate principal amount of $400 million, consisting of a $125 million term loan and a $275 million revolving credit facility. The New Bank Credit Facility, among other things, increases the available borrowings under the revolving credit facility from $250 million to $275 million and increases the size of the term loan from an initial balance of $100 million to $125 million, extends the maturity date to October 11, 2028 from May 12, 2026, and makes conforming changes to replace the Bloomberg Short-Term Bank Yield Index, or BSBY, to the secured overnight financing rate, or SOFR. Further, financial covenants were modified to remove the $100 million limit of netting unrestricted cash and cash equivalents when calculating the consolidated total leverage ratio, the consolidated secured leverage ratio, and to increase the consolidated total leverage ratio resulting in a "springing lien" event from 4:00 to 1.00 to 4.25 to 1.00. At the closing of the New Bank Credit Facility, CoreCivic received approximately $33.8 million of net borrowings before transaction costs as a result of the increased size of the term loan, and the revolving credit facility remains undrawn except for approximately $17.4 million in outstanding letters of credit.

08:08 EDT CPI Aerostructures delivers 1st B-52 radar rack structure to RTX - CPI Aerostructures (CVU) announced that it has delivered its first B-52 Radar Rack Structure to Raytheon (RTX), an RTX business under an IDIQ contract signed in late 2021 with a ceiling value of $20 million. Under this first phase of the IDIQ contract, CPI Aero is building and delivering 9 development units and 2 spares, along with completing the tooling and other non-recurring engineering efforts. Deliveries of the remaining rack structures will continue into 2024. "This B-52 program is one of multiple new programs on-boarded at CPI Aero in 2022, including multiple airborne pod structures supporting critical Intelligence, Surveillance, and Reconnaissance missions," said Dorith Hakim, president and CEO of CPI Aero. "CPI Aero is proud to support Raytheon on this important B-52 Radar Modernization Program. This first delivery demonstrates CPI Aero's continued commitment to manufacturing excellence in our Aerosystems business unit, the fastest growing segment of our business."

08:07 EDT Soluna Holdings announces 1-for-25 reverse stock split - Soluna Holdings, the parent company of Soluna Computing announced that it will execute a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25. The reverse stock split was approved by the Board of Directors and by shareholders at the annual meeting of the stockholders on June 29. The reverse stock split will become effective at 5:00 p.m. Eastern Time, on October 13. The Company's common stock will begin trading on a post-split basis at the market open on October 16 , under the Company's existing trading symbol "SLNH". At the effective time, every 25 issued and outstanding shares of the Company's common stock will be converted automatically into one share of the Company's common stock without any change in the par value per share. Once effective, the reverse stock split will reduce the number of shares of common stock issued and outstanding from approximately 37.3 million to approximately 1.5M. The reverse stock split is part of the Company's plan to regain compliance with the $1.00 per share minimum closing price required to maintain continued listing on NASDAQ

08:07 EDT Galectin Therapeutics nominates Benjamin Carson to board of directors - Galectin Therapeutics announced that Benjamin Carson, Sr. has been nominated to serve on the company's board of directors. Carson has served as a senior advisor to Galectin Therapeutics since 2021. He served as the program's director until retirement in 2013, and subsequently served as the 17th Secretary of Housing and Urban Development.

08:06 EDT Novocure teams with Stanford to create TTFields research program - Novocure announced it has entered into an agreement with Stanford University to establish the Stanford School of Medicine Tumor Treating Fields TTFields Research Program. The program is intended to support both preclinical studies and clinical trials with TTFields, electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. "We look forward to collaborating with Stanford Medicine to establish a research framework for preclinical and clinical development of TTFields," said Moshe Giladi, Ph.D., Novocure's Chief Science Officer. "Together, we will enable new discoveries into the mechanisms and treatment possibilities of TTFields, including new indications and uses of TTFields along with other therapies. We will pursue our mission to extend survival in some of the most aggressive forms of cancer while enhancing the education and scholarship of future clinicians and scientists."..."With this initiative, we will establish a research infrastructure for preclinical and clinical development of TTFields and of potential new indications and combination therapies using TTFields," said Michael Lim, M.D., Chair of the Department of Neurosurgery at Stanford Medicine. "We hope that this collaboration will educate, bring together, and inspire a diverse group of leaders in medicine and science who will help further our mission to deliver outstanding patient-centered care and improve human health through discovery, innovation, and education."

08:05 EDT Enphase Energy expands IQ8 microinveters into South Africa - Enphase Energ has entered the solar market in South Africa with the introduction of IQ8 Microinverters for grid-tied residential and small commercial applications, with peak output AC power of 480 W, to support newer high-powered solar modules.

08:03 EDT InMode sees Q3 adjusted gross margin 83%-85%

07:49 EDT Fusion Pharmaceuticals and AstraZeneca's FPI-2068 shows anti-tumor efficacy - Fusion Pharmaceuticals (FUSN) announced the presentation of preclinical data for FPI-2068, a clinical stage bispecific IgG-based targeted alpha therapy designed to deliver actinium-225 to various solid tumors that co-express EGFR-cMET. Fusion is jointly developing FPI-2068 with AstraZeneca (AZN) under the companies' multi-asset collaboration agreement. In the preclinical study, FPI-2068 demonstrated anti-tumor efficacy in colorectal and lung tumor xenograft mouse models, and single dose administration of FPI-2068 led to prolonged tumor regression. Further, FPI-2068 caused activation of the DNA damage response pathway as well as apoptosis, suggesting an inability of the cellular machinery to repair the DNA damage induced by the alpha radiation, consistent with the proposed primary mechanism of action. These data provide further evidence supporting the clinical development of FPI-2068, which is expected to enter a Phase 1 study for the treatment of solid tumors co-expressing EGFR-cMET. EGFR and cMET are both validated targets that are co-expressed in multiple tumor types, including head and neck squamous cell carcinoma, non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.

07:40 EDT Nextech3D.ai launches augmented reality wayfinding mobile app - The company said, "Nextech3D.AI is proud to announce a major milestone in the evolution of AR-powered event experiences. The Company's MapD business unit has integrated and launched its indoor navigation capabilities with ARway.ai's technology, opening up exciting new opportunities for event organizers. This integration sets the stage for events to now monetize the airspace with AR sponsorships and offer 3D /AR mobile games and other immersive experiences for events like never before. The integration between MapD and ARway.ai introduces a groundbreaking Augmented Reality Powered Event Mobile App. This technology unlocks a new revenue channel for event organizers through AR experiences available exclusively via the event mobile app. Event organizers can enjoy white glove deployment and sponsorship sales services, as well as a first-of-its-kind AR navigation experience at trade shows."

07:38 EDT Labrador Gold announces results from drilling at Appelton Fault Zone - Labrador Gold announces results from recent drilling targeting the highly prospective Appleton Fault Zone. The drilling is part of the Company's ongoing 100,000 metre diamond drilling program at its 100% owned Kingsway Project. "During the first phase of drilling at DropKick we demonstrated the presence of near surface gold over significant widths while increasing the strike length of known mineralization which remains open along strike in both directions. Further drilling is required to demonstrate the true potential of this discovery," said Roger Moss, President and CEO of LabGold. "Planning is currently underway for drilling in The Gap, between Big Vein and Pristine, and to the south of Big Vein towards the recent Knobby discovery. Drilling of targets in these areas is expected to begin before the end of the month. We are excited to start filling in the gaps between the four discoveries made along a 7 kilometre section of the Appleton Fault Zone at Kingsway."

07:37 EDT TC Energy appoints Kvisle as Chair of new Liquids Pipelines board of directors - TC Energy announces that industry leader Hal Kvisle has agreed to be appointed as Chair of the new Liquids Pipelines Company's Board of Directors. Today's announcement follows the July 27, 2023 disclosure that TC Energy plans to separate into two independent, investment-grade, publicly listed companies through the spinoff of its Liquids Pipelines business. TC Energy's decision to pursue the spinoff will allow TC Energy and the new Liquids Pipelines Company to maximize asset value by positioning both entities to fully leverage growth opportunities and meet the growing demand for their services. The Transaction is anticipated to be completed on a tax-free basis in the second half of 2024.

07:36 EDT Cyteir: Cohort of CYT-0851 in combo for ovarian cancer well tolerated - Cyteir Therapeutics presented ongoing results from a dose expansion cohort in its Phase 1 combination study of CYT-0851 with capecitabine in patients with platinum-refractory or -resistant ovarian cancer in a late-breaker poster titled "Phase 1 Dose Expansion Results of CYT-0851, a Monocarboxylate Transporter MCT Inhibitor, in Combination with Capecitabine in Platinum-Resistant Ovarian Cancer" at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics meeting in Boston, Massachusetts. "The results from the expansion cohort support the initial findings in our Phase 1 dose escalation study of CYT-0851 in combination with capecitabine in ovarian cancer," said Markus Renschler, MD, President and Chief Executive Officer of Cyteir, "confirming a high level of tumor control with an all-oral outpatient regimen that was generally well tolerated." The primary objective of the expansion cohort of the ongoing Phase 1 combination study is to determine in advanced platinum-resistant ovarian cancer patients the safety and tolerability of the CYT-0851 plus capecitabine combination. Other secondary objectives included the determination of pharmacokinetic parameters and to characterize the preliminary anti-tumor activity. The poster presents ongoing results for eleven evaluable patients with platinum-refractory or -resistant ovarian cancer treated in this expansion cohort.

07:35 EDT Red White & Bloom Brands selected as successful bidder in Aleafia Health sale - Red White & Bloom Brands Inc. (RWBYF) is providing an update on matters relating to Aleafia Health (ALEAF). RWB is pleased to announce that it has been selected as the successful bidder under the sale and investment solicitation process approved by the Ontario Superior Court of Justice in connection with the proceedings of Aleafia and certain of its subsidiaries under the Companies' Creditors Arrangement Act. On August 22, 2023, the Court approved, among other matters, the terms of a SISP which included a stalking horse asset purchase and share subscription agreement pursuant to which RWB would acquire certain assets from Aleafia Health and subscribe for shares of certain subsidiaries of Aleafia Health if RWB were to become the successful bidder pursuant to the SISP. As previously disclosed, the Stalking Horse Agreement provides for a reverse vesting transaction whereby a wholly-owned subsidiary of RWB would subscribe for shares of certain of Aleafia Health's subsidiaries and acquire specific intellectual property owned, licensed or leased by Aleafia Health. Certain excluded assets and liabilities of the Aleafia Purchased Entities would be transferred to one or more corporations that would not be included among the Aleafia Purchased Entities at closing. RWB's subsidiary would be the sole shareholder of the Aleafia Purchased Entities following closing. The consummation of the transactions contemplated under the Stalking Horse Agreement are subject to satisfaction or waiver of certain conditions set forth in the Stalking Horse Agreement, including, among other things, the Court granting the requisite approval and vesting order as a final order, receipt of all required regulatory approvals and Aleafia Group's Health Canada and cannabis excise licences being in good standing and continuing in good standing and not suspended or terminated following the closing date. The Approval Order hearing is set for October 27, 2023 and, should the Court issue the Approval Order, the parties anticipate closing the transactions contemplated under the Stalking Horse Agreement following satisfaction of the remaining conditions to closing, and in any event no later than November 22, 2023. At the October 27 hearing, RWB anticipates that the Aleafia Group will ask the Court for an extension of the current stay period in the Aleafia CCAA Proceedings that expires on October 31, 2023, in order to, among other things, permit the parties to complete the transactions contemplated under the Stalking Horse Agreement.

07:33 EDT Aleafia Health announces Red White & Bloom as successful bidder in sale - Aleafia Health (ALEAF) announces that Red White & Bloom Brands (RWBYF) has been selected as the successful bidder pursuant to the Court-approved sale and investment solicitation process in connection with the previously announced proceedings of Aleafia and certain of its subsidiaries under the Companies' Creditors Arrangement Act. On August 22, 2023, the Ontario Superior Court of Justice approved, among other matters, the terms of a SISP which included a stalking horse asset purchase and share subscription agreement pursuant to which RWB would acquire certain assets from Aleafia and subscribe for shares of certain subsidiaries of Aleafia if RWB were to become the successful bidder pursuant to the SISP. The Stalking Horse Agreement was approved by the Court in the context of the SISP, in order to establish the baseline consideration for the Corporation's business and assets. In addition, Aleafia has entered into a definitive purchase agreement pursuant to which it has agreed to sell its Grimsby facility to a third-party purchaser, which asset was excluded from the RWB Transaction and marketed separately under the SISP. In accordance with the terms of the SISP, Aleafia will be seeking Court approval of the Sale Transactions in connection with the SISP and authority to consummate the transactions provided for therein at the approval hearing which will be held on October 27, 2023. If approved by the Court, closing of the RWB Transaction is expected to occur prior to November 22, 2023, and closing of the Property Sale is expected to occur prior to November 1, 2023.

07:16 EDT Helius Medical receives LOI from Quebec MSSS to purchase 30 PoNS devices - Helius Medical Technologies announced that it has received a letter of intent, LOI, from the Quebec Ministry of Health and Social Services, MSSS, for the purchase of 30 Portable Neuromodulation Stimulator, PoNS, devices as part of an initiative to assess the value of using PoNS to treat patients suffering symptoms due to stroke. "Clinical evidence shows that stroke patients treated with PoNS experience significant improvement in gait and balance as well as a reduced risk of falling," said Dane Andreeff, Helius' President and Chief Executive Officer. "We are grateful that a second important Canadian healthcare provider has recognized the potential benefits of PoNS Therapy. A few weeks ago, the University of Montreal placed an order for ten PoNS devices to be used in a research study assessing stroke recovery, and the MSSS's initiative will allow 30 more patients to benefit from PoNS Therapy through MSSS's funding. We believe this order will accelerate adoption in Canada and, importantly, provide invaluable therapeutic evidence to support Helius' ongoing efforts to receive authorization for stroke in the United States." The sales of these PoNS devices are expected to commence in the fourth quarter of 2023 and extend through the first quarter of 2024.

07:15 EDT Olema Oncology KAT6 inhibitor compounds demonstrate anti-tumor activity - Olema Pharmaceuticals announced new preclinical data regarding the discovery of novel compounds targeting KAT6, an epigenetic target that is dysregulated in breast and other cancers. These data will be presented today at a poster session at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, ANE 2023, in Boston, Massachusetts. The poster, titled "The discovery of potent KAT6 inhibitors that demonstrate anti-tumor activity in preclinical models of ER+ breast cancer", describes the discovery and preclinical characterization of orally bioavailable, potent KAT6A and KAT6B-selective inhibitors developed by Olema in collaboration with Aurigene Oncology. The poster highlights that: Olema KAT6 compounds were selective and potent against KAT6A and KAT6B with greater than250-fold selectivity over other KAT family members, including the essential genes KAT5 and KAT8; In KAT6-amplified and overexpressing breast cancer cell lines, Olema KAT6 compounds strongly inhibited cell proliferation whereas KAT6-low cell lines were insensitive to the compounds; Olema KAT6 inhibitor compounds caused dose-dependent tumor growth inhibition and tumor regression comparable to or better than a positive-control patented KAT6 inhibitor; Olema KAT6 inhibitor compounds are orally bioavailable with desirable pharmacokinetics; Olema KAT6 inhibitor compounds demonstrate histone target engagement and efficacy, as well as synergism with palbociclib or palazestrant.

07:13 EDT EVgo announces $12.7M in preliminary awards during Q3 - EVgo announced it has been selected for more than $12.7M in preliminary awards from a variety of funding sources across California, Colorado, and Pennsylvania, including utilities, air districts, state energy offices, and state departments of transportation via the National Electric Vehicle Infrastructure NEVI formula program during the third quarter of 2023. In total, these new awards will support the buildout of more than 150 fast charging stalls. Since announcing in July 2023 that EVgo and its eXtend partners were awarded more than 75% of funds in Ohio's NEVI program, EVgo and its eXtend partners have been selected for more than $4.3 million in additional NEVI awards; this includes more than $1.5 million in Colorado supporting the construction of 14 stalls, and more than $2.8 million in funding in Pennsylvania supporting the construction of 18 stalls. To date, EVgo and its eXtend partners have been selected for approximately 20% of awarded NEVI funds, with additional announcements expected before the end of the year. All EVgo and eXtend stations to be built along corridors with NEVI funding will feature high-power 350kW fast charging to help EV drivers power up quickly and get back on the road.

07:11 EDT Xortx reports ISS recommends shareholders vote for share consolidation - XORTX Therapeutics announces that Institutional Shareholder Services has recommended that the Company's shareholders vote FOR the proposed share consolidation resolution at XORTX's special meeting of shareholders scheduled to be held at 3710 - 33rd Avenue NW, Calgary, Alberta, Canada T2L 2M1 at 10:00 a.m. (Calgary time), on Wednesday, October 25, 2023. Dr. Allen Davidoff, CEO and XORTX, stated, "Management and the Board of Directors wish to clear up any ambiguities that may have arisen from the Information Circular and recent press release regarding the upcoming special meeting of shareholders that seeks shareholder approval to consolidate the Company's shares. For clarification, the special meeting of shareholders seeks approval for a consolidation of the Company's shares in a range from 0 to 9:1 which is one option available to the Company to maintain good standing and remain in compliance with NASDAQ's $1 USD minimum bid price requirement. Approval to consolidate does not mean this is an irreversible process even after shareholder approval, as Management and the Board of Directors can decide to not proceed with the consolidation. For example, if XORTX shares were to trade at greater than $1 USD for more than 10 days, it would not be necessary to complete the reverse split. While it is not the preference of Management and the Board of Directors to consolidate the Company's shares, we remain committed to bringing XORTX into NASDAQ compliance as soon as possible." Benefits of the Share Consolidation: It is the position of XORTX' board of directors that the share consolidation is in the best interests of the Company, its shareholders, and other stakeholders and that the benefits of the share consolidation could include: Compliance with Minimum Bid Price Requirement for Continued Listing on Nasdaq; anticipated Higher Share Price; Increased Investor Interest

07:10 EDT Montauk Brewing releases Major Wave Chaser Double India Pale Ale - Montauk Brewing Company announced the launch of Major Wave Chaser Double India Pale Ale, a high-octane version of Montauk's best-selling Wave Chaser IPA brewed to satisfy the strong demand for full-flavor, high-alcohol beers. An approachable beer with endless tropical and pine flavors, Major Wave Chaer maintains the popular characteristics of Wave Chaser, with a bigger punch. It is available in single 19.2-ounce cans and 15-packs of 19.2-ounce cans.

07:07 EDT InspireMD supports CMS's final NCD expanding coverage of CAS - InspireMD announced its support for the Centers for Medicare and Medicaid Services, CMS, final National Coverage Determination, NCD, which expands coverage of carotid artery stenting, CAS, and transcarotid artery revascularization, TCAR, to include both asymptomatic and standard risk patients. Marvin Slosman, Chief Executive Officer of InspireMD, stated, "We support CMS's final decision on the expansion of coverage of CAS to include both symptomatic and asymptomatic carotid artery disease patients considered to be either standard or high risk for surgery. This decision offers a new treatment alternative to patients and their treating physicians and, we believe, will accelerate the ongoing shift toward an endovascular 'stent first' approach and away from more invasive surgery, the current standard of care." InspireMD will provide further updates on this and other recent developments during its regularly scheduled third quarter 2023 conference call in November.

07:05 EDT BioNTech and MediLink Therapeutics partner to develop anti-cancer antibody - BioNTech has entered into a strategic research collaboration and worldwide license agreement with MediLink Therapeutics on the development of a next-generation antibody-drug conjugate candidate against Human Epidermal Growth Factor Receptor 3, or HER3. MediLink will grant BioNTech exclusive global rights for the development, manufacturing, and commercialization of one of MediLink's ADC assets excluding Mainland China, Hong Kong Special Administrative Region, and Macau Special Administrative Region. In exchange, BioNTech will provide MediLink with an upfront payment totaling of $70M and additional development, regulatory and commercial milestone payments potentially totaling over $1B. The completion of the agreement is subject to customary closing conditions, including clearance under the HSR Antitrust Improvements Act. HER3 is a target that is overexpressed in various cancer types, such as non-small cell lung cancer and breast cancer and is closely associated with tumor metastasis and disease progression.

07:03 EDT Ginkgo Bioworks, QL AG partner to develop dairy proteins - QL AG, a food technology solutions company, announced a new collaboration to develop dairy proteins with Ginkgo Bioworks, which is building the leading platform for cell programming and biosecurity. QL AG will tap into Ginkgo's extensive capabilities in strain engineering across multiple chassis organisms to support its goal of providing the market with high-quality nutritionally equivalent dairy proteins.

07:02 EDT BioLineRx closes exclusive license agreement with Guangzhou Gloria Biosciences - BioLineRx announced the closing of an exclusive license agreement with Guangzhou Gloria Biosciences Co., and an associated investor for the development of motixafortide across all indications in Asia. Motixafortide is a novel, high-affinity CXCR4 inhibitor that received approval for its first indication in September 2023 by the U.S.FDA for stem cell mobilization in autologous stem cell transplantation in patients with multiple myeloma. Motixafortide is also being studied for other potential uses in oncologic and hematologic diseases. The license agreement provides for a $15M upfront payment (which was received at closing), up to $50M in potential development and regulatory milestones in China and Japan, and up to $200M in potential commercial milestones based on defined sales targets. BioLineRx is also eligible to receive tiered double-digit royalties on net sales. In addition, the transaction included an equity investment of $14.6M in BioLineRx through the purchase of newly issued American Depositary Shares at a price of $2.136 per ADS in a private placement. No warrants were issued in the transaction. Along with the investment, the purchaser received the right to appoint one representative to the BioLineRx Board of Directors.

06:59 EDT Computer Task Group and Cegeka extend tender offer expiration date - Computer Task Group and Cegeka Groep announced that Chicago Merger Sub, a wholly owned subsidiary of Cegeka, has extended the expiration date of its offer to acquire all of the outstanding shares of common stock of CTG, par value 1c per share, for $10.50 per Share, net to the seller in cash, without interest and less any applicable withholding taxes. The offer, which is scheduled to expire on October 13, has been extended until one minute after 11:59 p.m., Eastern Time, on November 3. The depositary for the offer has indicated that on October 11, approximately 8,259,806.406 Shares had been validly tendered, representing approximately 53.6755% of the outstanding Shares. The offer was extended to allow additional time to satisfy the Regulatory Conditions and the other conditions described in the Offer to Purchase.

06:57 EDT Eli Lilly announces mirikizumab met co-primary, major secondary endpoints - Eli Lilly announced that mirikizumab met the co-primary and all major secondary endpoints compared to placebo in VIVID-1, a Phase 3 study evaluating the safety and efficacy of mirikizumab for the treatment of adults with moderately to severely active Crohn's disease. The double-blind, treat-through trial included mirikizumab, placebo and active control arms. In VIVID-1, all patients in the active treatment arms from the 12-week induction period continued with their original therapy into the maintenance portion of the study up to Week 52. Placebo patients who did not achieve clinical response at Week 12 were switched to blinded mirikizumab treatment. The study included co-primary endpoints, which were: Proportion of participants achieving clinical response by patient reported outcomes at Week 12 and clinical remission at Week 52 compared to placebo. In the mirikizumab arm, a statistically higher proportion achieved clinical response at Week 12 and clinical remission at Week 52 compared to placebo. Proportion of participants achieving clinical response by PRO at Week 12 and endoscopic response at Week 52 compared to placebo. In the mirikizumab arm, a statistically higher proportion achieved clinical response at Week 12 and endoscopic response at Week 52 compared to placebo. In this double-blind placebo and active controlled trial - the first reported for an IL-23p19 antibody - mirikizumab achieved all individual and composite major secondary endpoints at Week 52 compared to placebo. Notably, of the patients who received mirikizumab, 54.1% achieved clinical remission at Week 52 compared to 19.6% of patients who received placebo. In addition, for the endpoint of clinical remission, mirikizumab demonstrated non-inferiority versus ustekinumab. For the endpoint of endoscopic response at Week 52, mirikizumab did not achieve superiority to ustekinumab although results with mirikizumab were numerically higher, particularly in the non-multiplicity controlled bio-failed population. The overall safety was consistent with the known safety profile of mirikizumab. The frequency of serious adverse events was greater in placebo than mirikizumab. The most common treatment-emergent adverse events reported among patients treated with mirikizumab were COVID-19, anemia, arthralgia, headache and upper respiratory tract infection. Additional adverse events of interest reported among patients treated with mirikizumab included infections, injection-site reactions, hypersensitivity, liver enzyme elevations, depression and suicidal thoughts. No major adverse cardiac events were observed in the mirikizumab arm. With these data, Lilly plans to submit a marketing application for mirikizumab in Crohn's disease to the Food and Drug Administration, or FDA, followed by submissions to other regulatory agencies around the world, in 2024. Full data from the Phase 3 VIVID program will be disclosed in publications and at upcoming congresses.

06:54 EDT Fastenal says digital footprint in Q3 represented 57.1% of sales - The company said, "Our Digital Footprint in the third quarter of 2023 represented 57.1% of our sales, an increase from 49.5% of sales in the third quarter of 2022."

06:53 EDT Commercial Metals expects Q1 performance to decline from Q4 - Matt said, "We expect first quarter consolidated financial performance to remain strong by historical standards, but decline from the fourth quarter as a result of seasonally lower shipments, steel product margin compression in North America, and the continuation of challenging market conditions in Europe. During the first quarter, we anticipate that our Europe operations will receive approximately $60 million from two large government rebate programs. The first is an annual CO2 credit estimated at $25 million, up from the $9.5 million received last year. The second is structured as a reimbursement by the Polish government for elevated energy costs incurred during the European energy crisis. Proceeds from this program are expected to be $35 million, and are calculated based on the magnitude of energy cost inflation in calendar year 2023 relative to the prior year baseline. These rebates are expected to drive a sequential improvement in Europe segment adjusted EBITDA."

06:31 EDT Fisker plans to open first Fisker Lounge in Shanghai, China - Fisker announced that it intends to open its first Fisker Lounge in Shanghai, China, continuing the roll-out of its China business. Fisker established an office in China in 2022 and earlier this year released additional details on its plans for the country, including the set-up of a delivery center in 2023. The announcement of the Fisker Lounge in Shanghai builds on this strategy, as Fisker Lounges serve existing and future customers by being located in high-traffic retail locations where consumers can experience the Fisker brand and get a closer look at Fisker vehicles. The company expects to open its Shanghai Lounge in December 2023 or January 2024. The Lounge will be located on Taicang Road.

06:03 EDT Hecla Mining reports Q3 silver production down 8% vs. previous quarter - Reports Q3 gold production up 11%, lead down 37%, zinc down 12% vs. previous quarter. "Silver production continues to grow with almost a million ounces more this year compared to the first three quarters last year," said Phillips Baker, Jr., CEO. "Despite less production at the Lucky Friday, Greens Creek's consistent performance and the ramp-up of Keno Hill should allow us to be within our 2023 guidance of 14.5 to 15.5 million ounces. Casa Berardi performed as expected during the third quarter as the transition to full open pit mining continues with completion expected in mid-2024. At Lucky Friday, we continue executing the plans to bring the mine back into production with no significant impact expected on 2024 production. With our silver production expected to increase to about 20 million ounces by 2025, Hecla remains the world's fastest-growing established silver producer, the largest in the U.S., and remains on track to become Canada's largest next year."

05:31 EDT AbbVie announces upadacitinib met primary endpoint - AbbVie announced that its Phase 2b study evaluating upadacitinib in adults with non-segmental vitiligo, or NSV, met the primary endpoint of percent change from baseline in the Facial Vitiligo Area Scoring Index, or F-VASI, at week 24 with the 11 mg and 22 mg doses versus placebo. The percent reduction from baseline in F-VASI at week 52 was numerically greater than results at week 24 for all upadacitinib doses.2 No new safety signals were identified beyond the known safety profile for upadacitinib. Based on these data, AbbVie is advancing its clinical program of upadacitinib in vitiligo to Phase 3. At week 24, upadacitinib achieved the primary endpoint of percent change from baseline in F-VASI with 11 mg and 22 mg doses versus placebo. F-VASI is a tool that measures re-pigmentation of the face and is used to assess the extent of re-pigmentation and treatment response in clinical trials.3 Higher response rates were also observed with upadacitinib versus placebo in secondary endpoints, including F-VASI 75 at week 24 with the 11 mg and 22 mg doses and Total Vitiligo Area Scoring Index 50 at Week 24 with the 22 mg dose. The mean percent reduction from baseline in F-VASI was numerically greater at week 52 than results at week 24 for all upadacitinib dose groups.2 In addition, response rates observed for F-VASI 75 and T-VASI 50 at week 52 were numerically greater than those at week 24 for all upadacitinib dose groups. No new safety signals were observed beyond the known safety profile for upadacitinib. Treatment-emergent adverse event, or TEAE, rates were generally similar with upadacitinib and placebo in period 1. Numerically higher rates of serious TEAEs and TEAEs leading to study drug discontinuation were observed in the upadacitinib 22 mg group versus the other groups. One death adjudicated as undetermined/unknown cause and deemed by the investigator to have no reasonable possibility of being related to study drug occurred in the upadacitinib 22 mg group. One adjudicated event of nonfatal ischemic stroke occurred with upadacitinib 11 mg in a patient with known cardiovascular risk factors. One event of malignancy occurred with upadacitinib 11 mg in a patient with positive family history of breast cancer. Throughout the study, a single event of serious infection was reported in the upadacitinib 22 mg group. There were no adjudicated events of venous thromboembolism, gastrointestinal perforation, or active tuberculosis. The use of upadacitinib in vitiligo is not approved and its safety and efficacy have not been evaluated by regulatory authorities. The 24-week data in this release and partial 52-week data are being presented as an oral presentation during the European Academy of Dermatology and Venerology, or EADV, Congress in Berlin, Germany, on October 12. The partial 52-week data is based on the data cutoff date of January 13. Approximately 58% of patients had an opportunity to reach 52-week at that time. The full 52-week data in this release will be presented at an upcoming medical meeting.

05:22 EDT Genentech announces new 10-year Ocrevus data - Genentech, a member of Roche, announced new clinical and real-world data for Ocrevus demonstrating its role in continuing to transform care for people living with relapsing or primary progressive multiple sclerosis, or RMS or PPMS, presented at the 9th Joint ECTRIMS-ACTRIMS Meeting. Ocrevus is the first and only disease-modifying treatment, or DMT, in MS to benefit both people with RMS and PPMS and now has 10 years of follow-up data from its three Phase III trials. After 10 years of continuous Ocrevus treatment, 77% of patients with RMS were free from disability progression based on 48-week confirmed disability progression, or CDP, events and 92% of patients were still walking unassisted. In patients with PPMS, 36% were free from disability progression based on 48-week CDP events and 80% of those patients treated continuously with Ocrevus over 10 years were still able to walk. These long-term data reinforce the critical importance of early treatment in preserving function across the MS spectrum, showing a lower risk of reaching disability events in patients with RMS and PPMS who initiated Ocrevus treatment earlier. New safety data from 6,155 patients with 28,269 patient-years of exposure to Ocrevus across 12 clinical trials further support the medicine's favorable benefit-risk profile, which has remained consistent over 10 years. The risk characteristics of Ocrevus in the all-exposure population, or RMS and PPMS, remained consistent with the characteristics observed during the controlled treatment periods. Serious infections and malignancy rates remain within the range reported for patients with MS in real-world registries. Longer exposure to Ocrevus did not lead to an increased risk of serious infections regardless of the immunoglobulin G (IgG) status of the patients (normal levels or levels below the lower limit of normal). No new or unexpected safety signals were seen in patients treated with Ocrevus in ongoing clinical trials. Family planning is an essential aspect in the care of women living with MS, many of whom are of child-bearing age. Genentech safety data from 3,253 cumulative pregnancies in women with MS do not suggest an increased risk of adverse pregnancy or infant outcomes in women with MS treated with Ocrevus. Outcomes were known for 1,145 prospectively reported pregnancies and 512 of these had in utero exposure to Ocrevus. Respective outcomes from these two groups were: 83.6% and 84.2% live births; 1.2% and 0.8% ectopic pregnancy; 5.1% and 7.4% elective terminations; 10.0% and 7.4% spontaneous abortions; less than0.1% and 0.2% still birth. In utero exposure to Ocrevus did not increase the risk of adverse pregnancy or infant outcomes compared with the epidemiological background of both the MS and general populations. Furthermore, a real-world analysis from the international MSBase registry based on data from 1,722 women living with MS receiving different DMTs suggests that women who conceived during Ocrevus treatment or soon after their last dose are at low risk for relapse during pregnancy and postpartum. During pregnancy, the annualized relapse rate, or ARR, was 0.00 for women previously treated with Ocrevus vs. 0.05 to 0.32 for other DMTs. The postpartum ARR was 0.09 for women treated with Ocrevus vs. 0.10 to 0.74 for other DMTs. Genentech is committed to generating further data on family planning priorities by assessing pregnancy and infant outcomes including infant B-cell levels through routine pharmacovigilance activities, post-marketing commitments and two ongoing Phase IV studies, MINORE and SOPRANINO. More than 300,000 people with MS have been treated with Ocrevus globally. Ocrevus is approved in more than 100 countries across North America, South America, the Middle East, Eastern Europe, Asia, Australia, Switzerland, the United Kingdom and the EU.

05:08 EDT Ares Management launches Ares European Strategic Income Fund - Ares Management announced the launch of Ares European Strategic Income Fund, or AESIF, a new open-ended direct lending fund that will provide individual investors in Europe and Asia with access to Ares' European direct lending strategy.